These findings are then summarized in simplified language across blogs and podcasts
doi: 10.1038/s41580-020-0278-0 [DOI] [PubMed] [Google Scholar] 50
Analysis of Specific Clinical Studies To better understand the limitations of the current evidence, lets examine some of the available studies on BPC-157: 1
And the exclusive focus on compounded injectables means no brand-name options, no oral formulations, and no alternative weight loss medications
#Nephrology #Dialysis #Semaglutide #GLP1 #Diabetes #Cardiovascular #EASD2025 #PatientSafety #MedicalResearch To view or add a comment, sign in How to individualize renoprotective therapy in obese patients with chronic kidney disease: a commentary by the Diabesity Working Group of the ERA Nephrology Dialysis Transplantation, Volume 40, Issue 10, October 2025, Pages 19771988, Published: 13 May 2025 The interrelated pandemics of obesity and type 2 diabetes mellitus (T2DM) are fuelling an increase in the prevalence of chronic kidney disease (CKD), which amplifies the risk of cardiovascular events and may progress to end-stage kidney disease (ESKD)
If youre looking for more information on interactions between GLP-1 medications and birth control or how taking weight-loss medications may impact your fertility, Dr
